POLITICO
Get the POLITICO Influence newsletter
Email
Sign Up
By signing up you agree to receive email newsletters or updates from POLITICO and you agree to our privacy policy and terms of service. You can unsubscribe at any time and you can contact us here. This sign-up form is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Presented by
With Daniel Lippman
PHARMA, MANUFACTURERS BLAST ADMINISTRATION OVER VACCINE PATENT WAIVERS: The Biden administration on Wednesday reversed course and said it supports waiving patent and other intellectual property protections for Covid-19 vaccines in a bid to ramp up production of the shots around the globe a victory for progressives who had pressured the administration and potentially a major blow for the pharmaceutical industry, which had lobbied heavily against the waiver.
March 2007
A. STEP-BD is the largest, federally-funded treatment study ever conducted for bipolar disorder
1. It is a long-term outpatient study that enrolled 4,360 participants from 22 sites over seven years (1998 to 2005). STEP-BD was designed to find out which treatments, or combinations of treatments, are most effective for treating episodes of depression and mania and for preventing recurrent episodes in people with bipolar disorder. STEP-BD is different from typical clinical trials that test one potential new treatment. It is a broad research program that includes several different studies, each aimed at a different aspect of treatment for the illness.
Multiple treatments, including medications and psychotherapies, currently are available for people with bipolar disorder, but doctors are often uncertain which of these treatments actually work best for specific aspects of the illness.
– According to the Alzheimer’s Association, one in three seniors dies with Alzheimer’s or another dementia. New Canaan Library is pleased to welcome Dr. Michael Lin, Associate Professor of Neurology, and acting director of the Weill Cornell Memory Disorders Clinic, to speak on this important topic. Dr. Lin will present his talk via live webinar on Tuesday, May 4 at 7 PM EST. Zoom sign in information will be provided upon registration at newcanaanlibrary.org.
Although statistics point to the fact that Alzheimer’s disease is quite common, it does not mean it is “normal” to lose memory as one ages. While some risk factors for Alzheimer’s cannot be altered, there are some things one can do that may reduce the potential of getting Alzheimer’s disease. Dr. Lin will address the factors and lifestyle choices that may reduce risks and discuss how doctors recognize Alzheimer’s disease. In addition, he will discuss how to prepare for Alzheimer’s disease the emotional, finan
Randomized trial results led to reduction in the use of minimally invasive surgery for cervical cancer
In a Correspondence article published in the April 29, 2021 issue of the
New England Journal of Medicine, researchers from University Hospitals (UH) Cleveland Medical Center, and New York Presbyterian Hospital - Weill Cornell Medicine in New York, found a substantial reduction in the use of minimally invasive surgery for cervical cancer after publication of the results a major study called the Laparoscopic Approach to Cervical Cancer (LACC) in November 2018.
The earlier study, which compared minimally invasive surgery with open abdominal radical hysterectomy in patients with early-stage cervical cancer, found that minimally invasive surgery was associated with worse disease-free and overall survival than open surgery. As a result of that study and other related studies, many guidelines recommended that surgeons use open surgery rather than minimally invasive surgery.
Share this article
WILMINGTON, Del., April 30, 2021 /PRNewswire/
DuPont (NYSE: DD) today announced the appointment of Deanna M. Mulligan to its Board of Directors, effective April 27, 2021. Following appointment, Ms. Mulligan was elected to the Board at the Company s Annual Meeting of Stockholders on April 28, 2021.
Deanna Mulligan We are pleased to welcome Deanna Mulligan to DuPont s Board of Directors, said, Ed Breen, DuPont Executive Chairman and Chief Executive Officer. As a veteran CEO, Deanna brings a wealth of experience in leadership, risk management and workforce strategies. Her strong commitment to corporate governance, social impact, and experience on numerous boards will provide DuPont with diverse and valuable insight.